Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Insurers step up pitch for Obamacare as government slashes its effort

President Donald Trump’s 90 percent cut to Obamacare advertising has U.S. health insurers in many states digging deeper into their pockets to get the word out about 2018 enrollment.

Read More »

TherapeuticsMD Soars on Plans to Resubmit TX-004HR NDA Without New Pre-Approval Study

Shares of TherapeuticsMD Inc. shot up more than 51 percent in morning trading after the U.S. Food and Drug Administration reversed course on its rejection of that company’s vaginal pain medication.

Read More »

FDA approves Roche drugs for rare types of blood, lung cancers

Roche Holding AG won U.S. approval to market its skin cancer drug Zelboraf for certain patients with Erdheim-Chester Disease, a rare type of blood cancer, and to market its drug Alecensa as a first choice of treatment for a subset of patients with non-small cell lung cancer.

Read More »

Mylan tweaks full-year forecasts on lift from Copaxone generic

Mylan NV raised the lower end of its 2017 forecasts as the U.S. drugmaker expects to benefit from the earlier-than-expected approval of its copycat of Teva’s blockbuster multiple sclerosis treatment Copaxone.

Read More »

Stelara shows promise against lupus in study

J&J’s blockbuster psoriasis drug Stelara led to a significant reduction in disease activity in patients with systemic lupus compared with a placebo in a mid-stage clinical trial.

Read More »

Bayer in bid to broaden use of anti-clotting drug Xarelto

German drugmaker Bayer moved to tap a potentially lucrative new market opportunity for its blockbuster clot prevention drug Xarelto, requesting approval in Europe to make atherosclerosis patients eligible for treatment.

Read More »

Novartis seeks EU approval for cell therapy Kymriah

Novartis submitted its cell therapy Kymriah for European approval in two forms of blood cancer, seeking to expand the use of the new treatment.

Read More »

Layoffs in California: Amgen to Slash 200 R&D Jobs, Genentech to Cut 130

Roche company Genentech indicated it is laying off 130 people at its facility in Vacaville, Calif. by the end of 2017. Amgen is reportedly eliminating about 200 R&D jobs, mostly in California, by the end of 2017.

Read More »

Mario Muredda Named CEO of Harrison and Star

Omnicom Health Group announced that Mario Muredda has been named CEO of Harrison and Star and former CEO Ty Curran has been promoted to chairman. The changes are effective January 1, 2018.

Read More »

Kirsten A. Kantak Appointed CEO of Biolumina

Omnicom Health Group announced that Kirsten A. Kantak was appointed CEO of Biolumina.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom